Theodoros Spinos

Dr. Theodoros Spinos

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2018 in Healthcare
Verified
Journal Article
Open access
PDF file
Chrysi KoliakiChrysi Koliaki
Chrysi Koliaki
TSTheodoros Spinos
Theodoros Spinos
ΜSΜarianna Spinou
Μarianna Spinou
ΜBΜaria-Eugenia Brinia
Μaria-Eugenia Brinia
DMDimitra Mitsopoulou
Dimitra Mitsopoulou
Nicholas KatsilambrosNicholas Katsilambros
Nicholas Katsilambros
Various dietary approaches with different caloric content and macronutrient composition have been recommended to treat obesity in adults. Although their safety and efficacy profile has been assessed in numerous randomized clinical trials, reviews and meta-analyses, the characteristics of the optimal dietary weight loss strategy remain controversial. This mini-review will provide general principles and practical recommendations for the dietary management of obesity and will further explore the components of the optimal dietary intervention. To this end, various dietary plans are critically discussed, including low-fat diets, low-carbohydrate diets, high-protein diets, very low-calorie diets with meal replacements, Mediterranean diet, and diets with intermittent energy restriction. As a general principle, the optimal diet to treat obesity should be safe, efficacious, healthy and nutritionally adequate, culturally acceptable and economically affordable, and should ensure long-term compliance and maintenance of weight loss. Setting realistic goals for weight loss and pursuing a balanced dietary plan tailored to individual needs, preferences, and medical conditions, are the key principles to facilitate weight loss in obese patients and most importantly reduce their overall cardiometabolic risk and other obesity-related comorbidities.

22 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
IKIason Kyriazis
Iason Kyriazis
TSTheodoros Spinos
Theodoros Spinos
ATArman Tsaturyan
Arman Tsaturyan
Panagiotis KallidonisPanagiotis Kallidonis
Panagiotis Kallidonis
JSJens Uwe Stolzenburg
Jens Uwe Stolzenburg
ELEvangelos Liatsikos
Evangelos Liatsikos
The purpose of this narrative review is to describe the different nerve-sparing techniques applied during radical prostatectomy and document their functional impact on postoperative outcomes. We performed a PubMed search of the literature using the keywords “nerve-sparing”, “techniques”, “prostatectomy” and “outcomes”. Other potentially eligible studies were retrieved using the reference list of the included studies. Nerve-sparing techniques can be distinguished based on the fascial planes of dissection (intrafascial, interfascial or extrafascial), the direction of dissection (retrograde or antegrade), the timing of the neurovascular bundle dissection off the prostate (early vs. late release), the use of cautery, the application of traction and the number of the neurovascular bundles which are preserved. Despite this rough categorisation, many techniques have been developed which cannot be integrated in one of the categories described above. Moreover, emerging technologies have entered the nerve-sparing field, making its future even more promising. Bilateral nerve-sparing of maximal extent, athermal dissection of the neurovascular bundles with avoidance of traction and utilization of the correct planes remain the basic principles for achieving optimum functional outcomes. Given that potency and continence outcomes after radical prostatectomy are multifactorial endpoints in addition to the difficulty in their postoperative assessment and the well-documented discrepancy existing in their definition, safe conclusions about the superiority of one technique over the other cannot be easily drawn. Further studies, comparing the different nerve-sparing techniques, are necessary.


Verified
Journal Article
Open access
PDF file
SKStamatios Katsimperis
Stamatios Katsimperis
NKNikolaos Kostakopoulos
Nikolaos Kostakopoulos
TBThemistoklis Bellos
Themistoklis Bellos
TSTheodoros Spinos
Theodoros Spinos
APAngelis Peteinaris
Angelis Peteinaris
ASAndreas Skolarikos
Andreas Skolarikos
The convergence of artificial intelligence and robotic surgery is redefining the management of genitourinary cancers by enhancing diagnostic accuracy, surgical precision, and training efficiency. This narrative review explores recent advancements in artificial intelligence applications across the cancer care continuum, with a focus on prostate, kidney, and bladder malignancies. Artificial intelligence tools, particularly those based on machine learning and deep learning, have demonstrated strong performance in analyzing imaging data, segmenting tumors, predicting pathological features, and supporting clinical decision-making. Intraoperatively, artificial intelligence enables skill assessment, personalized feedback, and real-time navigation by processing data from surgical videos and robotic system sensors. Augmented reality and intraoperative modeling further enhance visualization and margin control during complex procedures. The review also discusses emerging technologies such as single-port robotic platforms, which offer advantages in confined anatomical spaces and support less invasive approaches. Additionally, the growing field of telesurgery is addressed, highlighting its feasibility for complex urologic operations across vast distances. While many of these innovations are still in early stages of clinical validation, their integration into practice has the potential to improve oncologic and functional outcomes, expand access to expert care, and foster the development of next-generation surgical strategies in urologic oncology.

4 August 2023 in BJU International
Verified
Journal Article
Closed access
PKPanagiotis Kallidonis
Panagiotis Kallidonis
TSTheodoros Spinos
Theodoros Spinos
APAngelis Peteinaris
Angelis Peteinaris
BSBhaskar Somani
Bhaskar Somani
ELEvangelos Liatsikos
Evangelos Liatsikos

22 February 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
NKNikolaos Kalampokis
Nikolaos Kalampokis
CZChristos Zabaftis
Christos Zabaftis
TSTheodoros Spinos
Theodoros Spinos
MKMarkos Karavitakis
Markos Karavitakis
ILIoannis Leotsakos
Ioannis Leotsakos
DMDionysios Mitropoulos
Dionysios Mitropoulos
(1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2) Methods: A narrative review of all the available literature was performed. Only “landmark” publications were included. (3) Results: Overall, the number of PCa patients who harbor a BRCA2 mutation range between 1.2% and 3.2%. However, BRCA2 and BRCA1 mutations are responsible for most cases of hereditary PCa, increasing the risk by 3–8.6 times and up to 4 times, respectively. These mutations are correlated with aggressive disease and poor prognosis. Gene testing should be offered to patients with metastatic PCa, those with 2–3 first-degree relatives with PCa, or those aged < 55 and with one close relative with breast (age ≤ 50 years) or invasive ovarian cancer. (4) Conclusions: The individualized assessment of BRCA mutations is an important tool for the risk stratification of PCa patients. It is also a population screening tool which can guide our risk assessment strategies and achieve better results for our patients and their families.